{"entity":{"id":"nct07805551","kind":"trial","name":"A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer","aka":[],"tldr":"A phase 1/2 trial of HDM2017, Bevacizumab, CAPOX in colorectal cancer, run by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., now recruiting.","summary":"A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer is a phase 1/2 interventional study registered as NCT07805551 by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., with 220 participants planned, started 2026-08-18 and due to reach its primary completion in 2030-08. Interventions recorded: HDM2017, Bevacizumab, Oxaliplatin, Fluorouracil, Capecitabine. Conditions listed: CRC, Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07805551","url":"https://clinicaltrials.gov/study/NCT07805551"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["hdm2017","bevacizumab","capox","fluorouracil","capecitabine","flot"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07805551","phase":"1/2","setting":"A Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HDM2017 Combination Therapy in Participants With Advanced Colorectal Cancer","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","participation":[{"nct":"NCT07805551","source":"https://clinicaltrials.gov/study/NCT07805551","fetchedAt":"2026-10-07T16:56:51.027Z","studySha256":"5d2d7f834f97eb9d813084df8628c8517a2d50cdb454ca5c6e1b3740401d7651","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-04","leadSponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":220,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-08-18","startedType":"actual","enrolled":220,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07805551/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"hdm2017","kind":"drug","name":"HDM2017","route":"/drugs/hdm2017/"}]}}